• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Acta neurovegetativa

    Acta neurovegetativa

    JournalISSN 0375-9245

    年发文量

    研究主题

    论文(8083)

    排序
    1The Effect of Levodopa on Non-Motor Symptoms in Parkinson’s Disease: the G​ood, the B​ad and the U​gly
    Bruno Bergmans

    The lack of dopamine through the degeneration of the nigrostriatal pathways is responsible for most of the cardinal motor symptoms of Parkinson’s disease. Ever since the seminal New England paper by dr. George Cotzias describing the clinical effect of the administration of the dopamine precursor levodopa, the main research focus has often been on motor symptoms. Non-motor symptoms and non-motor fluctuations can also be very troublesome to patients. To shed more light on these often-neglected symptoms, this review will focus on the clinical aspects of a variety of non-motor symptoms in Parkinson’s disease, discussing the evidence and lack thereof for levodopa improving (the g​ood), having no effect (the b​ad), or even causing or worsening certain non-motor symptoms​ (the u​gly). The largest body of evidence supports a role for levodopa in the treatment of non-motor fluctuations. More dedicated clinical trials as well as novel therapies targeting non-dopaminergic mechanisms are needed to better address many non-motor symptoms.

    2026
    引用
    AI阅读
    加入学术空间
    2AlcoRhythm Vs. Algorithm: is a Stepped Approach to Parkinson’s Therapy Still Sensible?
    Wolfgang H. Jost
    2026
    引用
    AI阅读
    加入学术空间
    3How to Determine the Suitability of Parkinson’s Disease Patients for Device-Aided Therapies: a Practical Approach
    Teus van Laar, Anton Adriaan van der Plas

    Device‑aided therapies (DATs) are important treatment options for people with Parkinson’s disease whose symptoms can no longer be adequately controlled with oral or transdermal medication. They offer the potential to maintain or restore quality of life when conventional approaches are insufficient. Identifying which individuals with PD should be referred for DAT assessment, and then selecting the most appropriate therapy for each individual, requires careful evaluation of multiple factors. These extend beyond efficacy and tolerability to include practical, real‑world considerations shaped by a person’s personal circumstances, preferences, and care systems. To support clinicians in the initial step of recognizing when a person may be ready to transition to a DAT, several screening tools have been developed. Among these, D‑DATS is a practical, precise, and easy‑to‑use three‑factor tool designed for routine clinical practice. Validation studies indicate that D‑DATS outperforms commonly used criteria such as the ‘5‑2‑1’ rule and MANAGE‑PD, with respect to its specificity, reducing unnecessary or premature referrals. This article reviews the importance of accurate selection of suitable people with PD using a precise tool such as D‑DATS, and explores the real‑world considerations that can help guide the choice between DAT options. As motor efficacy, expressed as the reduction in the number of daily OFF-time hours, is broadly comparable across all DATs, the final decision often hinges on additional factors, like safety, long-term maintenance, and practical and patient‑centered factors. To support this process, we propose a decision‑tree flow chart to help clinicians navigate therapy selection in partnership with their patients. Ultimately, shared decision‑making, supported by ongoing reassessment and monitoring, is essential to ensure the long‑term success of whichever DAT is chosen.

    2026
    引用
    AI阅读
    加入学术空间
    4The CheckBRAIN™ Platform: Architecture for Post-Screening Brain Health Care Across the Parkinson’s Disease Continuum
    Roongroj Bhidayasiri,Jirada Sringean,Chanawat Anan,Saisamorn Phumphid, Teerawat Laosombut, Natthaphat Leabthong,Onanong Phokaewvarangkul,Pattamon Panyakaew,Surasa Khongprasert, Narumol Sukmueng, Punkorn Dornbunlon, Sirapatsorn Aksornpukdi,

    Parkinson’s disease (PD) screening can identify people needing clinical assessment but does not itself provide continuing care. Drawing on Thailand’s smartphone-based CheckPD implementation and selected literature, this conceptual review proposes CheckBRAIN, a platform linking screening to personalised brain-health care. All CheckPD participants would be offered voluntary entry, while clinician-led assessment would proceed without delay when clinically indicated. Concerning screening results, new or progressive symptoms, clinically defined high-risk syndromes, diagnostic uncertainty or medication-related problems would trigger clinical review, while people with established PD could enter directly. A personal brain-health portfolio links multidomain functioning, systemic and environmental context, priorities, actions, responsible persons or services and review dates. The six-domain SHAPES framework supports priority setting without creating another diagnostic score. Actions may include diagnostic assessment, medication review or pharmacotherapy, rehabilitation, cue-linked daily habits, social support, and service-level responses to practical barriers such as transport, digital access, referral navigation or unavailable services. Primary-care teams would coordinate longitudinal review, community workers would support assisted or non-digital participation, and specialists would contribute according to clinical need. Intended benefits include understandable next steps, fewer unresolved referrals, support for everyday function and participation, and clearly defined roles for care partners with the participant’s consent. We outline staged co-design and evaluation of feasibility, safety, functioning, participation, caregiver burden, equity, service use and costs. CheckBRAIN is not intended as a population registry and has no fixed national enrolment target. It remains a proposed care architecture, not a validated intervention or evidence of PD prevention or cost saving. Its intended contribution is accountable continuity between identified needs, appropriate care and reviewed outcomes.

    2026
    引用
    AI阅读
    加入学术空间
    5Clinical Correlates of Cognitive Impairment in Progressive Supranuclear Palsy and Multiple System Atrophy: a Comparative Neuropsychological Study
    P. M. Athira,Keshav J. Kumar,Shweta Prasad, T. V. Geethu, Manasi Harish,Saikat Dey, K. Ravichandiran, Ayush Kataria, Shyam Mohan,Nitish Kamble,Vikram V. Holla,Rohan R. Mahale,

    Atypical Parkinsonian Syndromes (AP), such as Progressive Supranuclear Palsy (PSP), Multiple System atrophy (MSA), are characterized by motor and non-motor symptoms. Although cognitive impairment is a core feature of AP, its differential profile across AP syndromes has been inadequately understood, particularly in underrepresented populations like in India. To compare cognitive and neuropsychological profiles in PSP and MSA and examine their clinical correlates. In this cross-sectional study, AP patients underwent cognitive assessment using the Frontal Assessment Battery (FAB), the Montreal Cognitive Assessment (MoCA), the Addenbrooke’s Cognitive Examination-III (ACE-III), and selected neuropsychological tests from the NIMHANS Neuropsychology Battery for the elderly (NNBE). Between-group comparisons were conducted using age-adjusted ANCOVA. Partial correlations examined associations between cognition and clinical variables within each group. A total of 159 patients were included in which PSP (n = 98, mean age 62.5 ± 7.4 years) was older than MSA (n = 61, 58.6 ± 7.8 years). Groups were gender-matched (p = 0.48). After age adjustment and FDR correction, PSP showed significantly lower scores than MSA on FAB, MoCA, and ACE-III Total, as well as on fluency, attention, visuospatial construction, and visuospatial working memory measures (all corrected p < 0.05). In PSP, cognitive performance correlated with education, motor severity (UPDRS-III, PSPRS), and mood (all p < 0.05), whereas in MSA, cognition correlated only with education and multilingualism, with no significant association with motor or symptom severity. PSP demonstrates greater global and domain-specific cognitive impairment than MSA, particularly in fluency and working memory, with cognition more closely tied to motor and mood burden. In MSA, cognition is more closely tied to premorbid reserve (education, multilingualism) than to disease severity. Routine cognitive screening may aid early differentiation and clinical management of AP.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 8083 篇论文

    高被引作者

    作者引用发文
    Peter Riederer11418132
    Arvid Carlsson552364
    Johannes Kornhuber420568
    Moussa Youdim393141
    Kurt Jellinger378861
    Klaus-Peter Lesch373946
    Heiko Braak29385
    H Beckmann286319
    Manfred Gerlach276353
    Udo Rüb24113

    高产作者

    作者引用发文
    Peter Riederer11418132
    Johannes Kornhuber420568
    Arvid Carlsson552364
    Kurt Jellinger378861
    Dirk Dressler145061
    Jost W. Lussi150957
    Manfred Gerlach276353
    Thomas Müller141449
    Heinz Reichmann170147
    Klaus-Peter Lesch373946

    相关期刊

    Anatomy and embryology
    Journal of neural transmission. Parkinson's disease and dementia section
    Monographs in neural sciences
    NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics
    Brain plasticity (Amsterdam, Netherlands)
    Biomarkers in neuropsychiatry
    AIMS Neuroscience
    eNeurobiologia
    Journal of Huntingtons Disease
    NeuroImage-Clinical